Bombesin antagonists have not been explored in COPD, and therefore preclinical studies focused on inhibiting bombesins might be of particular interest
Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy
Lilly intends to submit the drug to regulators by the end of 2025, positioning it as the first oral GLP-1 receptor agonist approved specifically for obesity
Researchers comment that a single introduction of the peptide may upregulate growth hormone production by somatotrophs for prolonged periods of time, thus apparently contributing to an overall increase in [growth hormone] secretion by 46% and also potentially upregulating its main anabolic mediator insulin-like growth factor-1 (IGF-1) by 45% on average
Because the body produces L-Carnitine on its own, it cannot be classified as a vitamin, even though it has functions similar to B vitamins
However, these accounts remain personal experiences, not peer-reviewed clinical trials